FIGURE 6 from Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
Year: 2023
Type: other
Abstract: HDAC and PI3K/AKT pathway inhibition in NCI-H660 and C4-2B cells in vitro. Cell viability assays of C4-2B (A) and NCI-H660 (B) cells in response to romidepsin and ipatasertib combination treatment or C4-2B (C) and NCI-H660 (D) cells in response to romidepsin and BYL719 or AZD8186 combination treatment and fimepinostat for 96 hours in vitro. Experiments were repeated a minimum of three times. Results are expressed as percent viable cells and are normalized to vehicle-treated controls. Caspase 3/7 activity after romidepsin, ipatasertib, BYL719, or AZD8186 combination treatment of C4-2B (E) and NCI-H660 (F) cells for 48 hours in vitro. Cell-cycle analysis after romidepsin, ipatasertib, BYL719, or AZD8186 combination treatment of C4-2B (G) and NCI-H660 (H) cells for 48 hours in vitro. P values = *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
Authors: Ailin Zhang, Nathan A. Lau, Alicia Wong, Lisha G. Brown, Ilsa M. Coleman, Navonil De Sarkar, Dapei Li, Diana C. DeLucia, Mark P. Labrecque, Holly M. Nguyen, Jennifer L. Conner, Ruth F. Dumpit, Lawrence D. True, Daniel W. Lin, Eva Corey, Joshi J. Alumkal, Peter S. Nelson, Colm Morrissey, John K. Lee
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4388825869